JP2017505114A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505114A5 JP2017505114A5 JP2016538525A JP2016538525A JP2017505114A5 JP 2017505114 A5 JP2017505114 A5 JP 2017505114A5 JP 2016538525 A JP2016538525 A JP 2016538525A JP 2016538525 A JP2016538525 A JP 2016538525A JP 2017505114 A5 JP2017505114 A5 JP 2017505114A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- modified serpin
- rcl
- serpin
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008847 Serpin Human genes 0.000 claims 39
- 108050000761 Serpin Proteins 0.000 claims 39
- 239000003001 serine protease inhibitor Substances 0.000 claims 39
- 230000035772 mutation Effects 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102100030500 Heparin cofactor 2 Human genes 0.000 claims 3
- 102100024078 Plasma serine protease inhibitor Human genes 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 102100022977 Antithrombin-III Human genes 0.000 claims 2
- 102100033299 Glia-derived nexin Human genes 0.000 claims 2
- 108090000481 Heparin Cofactor II Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 108010001953 Protein C Inhibitor Proteins 0.000 claims 2
- 229940122929 Protein C inhibitor Drugs 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims 1
- 102100035991 Alpha-2-antiplasmin Human genes 0.000 claims 1
- 108090000935 Antithrombin III Proteins 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 101710183811 Glia-derived nexin Proteins 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims 1
- 101000783712 Homo sapiens Alpha-2-antiplasmin Proteins 0.000 claims 1
- 101000757319 Homo sapiens Antithrombin-III Proteins 0.000 claims 1
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 claims 1
- 101001082432 Homo sapiens Heparin cofactor 2 Proteins 0.000 claims 1
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 claims 1
- 101001053641 Homo sapiens Plasma serine protease inhibitor Proteins 0.000 claims 1
- 102100023012 Kallistatin Human genes 0.000 claims 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 102000017975 Protein C Human genes 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- 102000012607 Thrombomodulin Human genes 0.000 claims 1
- 108010079274 Thrombomodulin Proteins 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000004019 antithrombin Substances 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010025221 plasma protein Z Proteins 0.000 claims 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322091.8A GB201322091D0 (en) | 2013-12-13 | 2013-12-13 | Modified serpins for the treatment of bleeding disorders |
| GB1322091.8 | 2013-12-13 | ||
| PCT/EP2014/077783 WO2015086854A1 (en) | 2013-12-13 | 2014-12-15 | Modified serpins for the treatment of bleeding disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018204779A Division JP6723319B2 (ja) | 2013-12-13 | 2018-10-31 | 出血性障害の治療に対する改変セルピン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505114A JP2017505114A (ja) | 2017-02-16 |
| JP2017505114A5 true JP2017505114A5 (enExample) | 2018-06-28 |
| JP6431541B2 JP6431541B2 (ja) | 2018-11-28 |
Family
ID=50030900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538525A Active JP6431541B2 (ja) | 2013-12-13 | 2014-12-15 | 出血性障害の治療に対する改変セルピン |
| JP2018204779A Active JP6723319B2 (ja) | 2013-12-13 | 2018-10-31 | 出血性障害の治療に対する改変セルピン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018204779A Active JP6723319B2 (ja) | 2013-12-13 | 2018-10-31 | 出血性障害の治療に対する改変セルピン |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9982035B2 (enExample) |
| EP (2) | EP3080157B1 (enExample) |
| JP (2) | JP6431541B2 (enExample) |
| KR (2) | KR101954945B1 (enExample) |
| CN (2) | CN110330563B (enExample) |
| AU (2) | AU2014363359B2 (enExample) |
| CA (1) | CA2933508C (enExample) |
| CY (1) | CY1121267T1 (enExample) |
| DK (1) | DK3080157T3 (enExample) |
| EA (1) | EA034050B1 (enExample) |
| ES (1) | ES2704058T3 (enExample) |
| GB (1) | GB201322091D0 (enExample) |
| HR (1) | HRP20182138T1 (enExample) |
| HU (1) | HUE042763T2 (enExample) |
| IL (2) | IL246180B (enExample) |
| LT (1) | LT3080157T (enExample) |
| MX (1) | MX357941B (enExample) |
| NZ (1) | NZ721918A (enExample) |
| PL (1) | PL3080157T3 (enExample) |
| PT (1) | PT3080157T (enExample) |
| RS (1) | RS58191B1 (enExample) |
| SI (1) | SI3080157T1 (enExample) |
| SM (1) | SMT201900016T1 (enExample) |
| TR (1) | TR201819781T4 (enExample) |
| WO (1) | WO2015086854A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| GB201322091D0 (en) | 2013-12-13 | 2014-01-29 | Cambridge Entpr Ltd | Modified serpins for the treatment of bleeding disorders |
| JP6890831B2 (ja) | 2015-07-08 | 2021-06-18 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖ予備免疫化および免疫療法 |
| IL297238B2 (en) | 2016-01-15 | 2024-08-01 | American Gene Tech Int Inc | Methods and preparations for gamma-delta T-cell activation |
| WO2017139065A1 (en) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| US10767183B2 (en) | 2016-03-09 | 2020-09-08 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| JP7173548B2 (ja) | 2016-06-08 | 2022-11-16 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | 非組み込みウイルス送達系およびその関連方法 |
| EP3481418A4 (en) | 2016-07-08 | 2020-03-11 | American Gene Technologies International Inc. | PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV |
| EP3585808B1 (en) * | 2017-02-23 | 2021-11-10 | Preclinics Gesellschaft für präklinische Forschung mbH | Modified serpins for the treatment of bradykinin-mediated disease |
| CA3057142A1 (en) | 2017-04-03 | 2018-10-11 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| RU2663464C1 (ru) * | 2018-02-26 | 2018-08-06 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Комбинаторная терапия для лечения геморрагического шока |
| AU2019369403B2 (en) * | 2018-10-29 | 2025-04-17 | Spin Therapeutics, Llc | Compositions and methods for alpha-1-antitrypsin disorders |
| CN110051830A (zh) * | 2019-03-14 | 2019-07-26 | 苏州新凝生物医药科技有限公司 | 一种protease nexin II\KPI蛋白突变体的应用 |
| US20240051991A1 (en) * | 2021-04-20 | 2024-02-15 | University Of Louisville | Recombinant Miropin |
| US20250066436A1 (en) | 2021-12-22 | 2025-02-27 | Royal College Of Surgeons In Ireland | A conjugate for use in localising a molecule to the vascular endothelium |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711848A (en) | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
| FR2599752B1 (fr) | 1986-06-10 | 1989-11-03 | Transgene Sa | Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine |
| DE3705745A1 (de) | 1987-02-23 | 1988-09-01 | Behringwerke Ag | Protein c-inhibitor (pci) als pharmazeutikum und in vitro-diagnostikum, verfahren zur herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci |
| US5612194A (en) | 1989-06-23 | 1997-03-18 | Trustees Of The University Of Pennsylvania | Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors |
| IE902276A1 (en) | 1989-06-26 | 1991-01-16 | Akzo Nv | Serpin variants |
| WO1998022125A1 (en) | 1996-11-19 | 1998-05-28 | Saulius Butenas | Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties |
| WO2001055390A1 (en) | 2000-01-28 | 2001-08-02 | Human Genome Sciences, Inc. | Human serpin polynucleotides, polypeptides, and antibodies |
| JP2002010783A (ja) | 2000-06-29 | 2002-01-15 | Jcr Pharmaceuticals Co Ltd | 改変型ヒトプロテインｃインヒビター |
| US6924267B2 (en) | 2001-09-18 | 2005-08-02 | Suomen Punainen Risti Veripalvelu | Methods and active substances for protecting organs |
| JP2003093063A (ja) | 2001-09-20 | 2003-04-02 | Jcr Pharmaceuticals Co Ltd | 改変型ヒトプロテインｃインヒビター |
| WO2003039585A1 (en) | 2001-11-09 | 2003-05-15 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors |
| FR2836143B1 (fr) | 2002-02-21 | 2004-04-16 | Servier Lab | Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2004056309A2 (en) | 2002-12-05 | 2004-07-08 | Socratech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| EP1567199B1 (en) | 2002-12-05 | 2014-07-23 | Zz Biotech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| WO2006090282A2 (en) * | 2005-02-28 | 2006-08-31 | Universite De Lausanne | Recombinant inhibitor proteins of an hk14 protease and use thereof |
| WO2006112451A1 (ja) | 2005-04-18 | 2006-10-26 | Mie University | プロテインｃインヒビターを含有する抗癌剤 |
| ES2726752T3 (es) * | 2005-12-15 | 2019-10-09 | Gulfstream Aerospace Corp | Entrada de compresión isentrópica para aviones supersónicos |
| NZ574140A (en) * | 2006-07-05 | 2012-02-24 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
| WO2008059043A2 (en) | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Combination of coagulation factor viii with apc-resistant factor v |
| WO2008059041A2 (en) | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Complementation of factor xi deficiency by factor v mutants |
| WO2008059009A2 (en) | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Factor v mutants for hemostasis in hemophilia |
| JP2010533684A (ja) | 2007-07-20 | 2010-10-28 | ユニベルシテ パリ サッド １１ | 血液凝固異常の治療又は予防のための変異アンチトロンビンの使用 |
| GB0714649D0 (en) | 2007-07-27 | 2007-09-05 | Univ Leuven Kath | Novel viral replication inhibitors |
| US8153766B2 (en) | 2007-10-26 | 2012-04-10 | Oklahoma Medical Research Foundation | Monoclonal antibodies against activated protein C |
| EP2055783A1 (en) * | 2007-10-30 | 2009-05-06 | VIB vzw | Insect inhibiting plant serpin mutants |
| CN101965409A (zh) | 2007-11-01 | 2011-02-02 | 罗切斯特大学 | 具有增加的稳定性的重组因子viii |
| CN110522905A (zh) * | 2008-01-21 | 2019-12-03 | 德莫迪斯公司 | 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 |
| US8822654B2 (en) | 2009-01-16 | 2014-09-02 | Universite Paris—Sud XI | Mutated antithrombins, a process for preparing the same and their use as drugs |
| BRPI1006443B1 (pt) * | 2009-04-22 | 2021-05-25 | Alteogen, Inc | Proteína ou peptídeo de fusão e método para aumentar a meia-vida in vivo de uma proteína ou peptídeo |
| US8557961B2 (en) * | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| CN105431165A (zh) | 2013-05-15 | 2016-03-23 | 莫尔研究应用有限公司 | 用于治疗心肺手术后的术后并发症的组合物和方法 |
| GB201322091D0 (en) | 2013-12-13 | 2014-01-29 | Cambridge Entpr Ltd | Modified serpins for the treatment of bleeding disorders |
| EP3585808B1 (en) * | 2017-02-23 | 2021-11-10 | Preclinics Gesellschaft für präklinische Forschung mbH | Modified serpins for the treatment of bradykinin-mediated disease |
-
2013
- 2013-12-13 GB GBGB1322091.8A patent/GB201322091D0/en not_active Ceased
-
2014
- 2014-12-15 EA EA201691235A patent/EA034050B1/ru unknown
- 2014-12-15 TR TR2018/19781T patent/TR201819781T4/tr unknown
- 2014-12-15 WO PCT/EP2014/077783 patent/WO2015086854A1/en not_active Ceased
- 2014-12-15 ES ES14827185T patent/ES2704058T3/es active Active
- 2014-12-15 PT PT14827185T patent/PT3080157T/pt unknown
- 2014-12-15 CA CA2933508A patent/CA2933508C/en active Active
- 2014-12-15 SI SI201430967T patent/SI3080157T1/sl unknown
- 2014-12-15 RS RS20181470A patent/RS58191B1/sr unknown
- 2014-12-15 JP JP2016538525A patent/JP6431541B2/ja active Active
- 2014-12-15 US US15/103,420 patent/US9982035B2/en active Active
- 2014-12-15 PL PL14827185T patent/PL3080157T3/pl unknown
- 2014-12-15 NZ NZ721918A patent/NZ721918A/en unknown
- 2014-12-15 KR KR1020167018756A patent/KR101954945B1/ko active Active
- 2014-12-15 EP EP14827185.1A patent/EP3080157B1/en active Active
- 2014-12-15 LT LTEP14827185.1T patent/LT3080157T/lt unknown
- 2014-12-15 HU HUE14827185A patent/HUE042763T2/hu unknown
- 2014-12-15 MX MX2016007711A patent/MX357941B/es active IP Right Grant
- 2014-12-15 EP EP18190334.5A patent/EP3434689A1/en not_active Withdrawn
- 2014-12-15 DK DK14827185.1T patent/DK3080157T3/en active
- 2014-12-15 HR HRP20182138TT patent/HRP20182138T1/hr unknown
- 2014-12-15 CN CN201910704484.0A patent/CN110330563B/zh active Active
- 2014-12-15 SM SM20190016T patent/SMT201900016T1/it unknown
- 2014-12-15 KR KR1020197006015A patent/KR102186924B1/ko active Active
- 2014-12-15 AU AU2014363359A patent/AU2014363359B2/en active Active
- 2014-12-15 CN CN201480075522.6A patent/CN105992771B/zh active Active
-
2016
- 2016-06-13 IL IL246180A patent/IL246180B/en active IP Right Grant
-
2018
- 2018-05-04 US US15/971,692 patent/US10351619B2/en active Active
- 2018-10-31 JP JP2018204779A patent/JP6723319B2/ja active Active
- 2018-11-08 IL IL262879A patent/IL262879A/en unknown
- 2018-12-17 AU AU2018279054A patent/AU2018279054A1/en not_active Abandoned
- 2018-12-27 CY CY20181101396T patent/CY1121267T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505114A5 (enExample) | ||
| Kelly-Robinson et al. | The serpin superfamily and their role in the regulation and dysfunction of serine protease activity in COPD and other chronic lung diseases | |
| Yaron et al. | Fibrinolytic serine proteases, therapeutic serpins and inflammation: fire dancers and firestorms | |
| Rau et al. | Serpins in thrombosis, hemostasis and fibrinolysis | |
| Aslam et al. | Serpina3n: potential drug and challenges, mini review | |
| Reed et al. | α2-antiplasmin: new insights and opportunities for ischemic stroke | |
| Chen et al. | Fasxiator, a novel factor XIa inhibitor from snake venom, and its site‐specific mutagenesis to improve potency and selectivity | |
| JP2011528913A5 (enExample) | ||
| CN105164152B (zh) | 作为靶向试剂的gla结构域 | |
| Verhamme et al. | Proteases: pivot points in functional proteomics | |
| Steinmetzer et al. | Fibrinolysis inhibitors: Potential drugs for the treatment and prevention of bleeding | |
| JP2013502458A5 (enExample) | ||
| EA201691235A1 (ru) | Модифицированные серпины для лечения нарушений свертываемости крови | |
| JP2014513952A5 (enExample) | ||
| Ziliotto et al. | Hemostasis components in cerebral amyloid angiopathy and Alzheimer’s disease | |
| Moh’d A et al. | Biochemical and structural insights into mesotrypsin: an unusual human trypsin | |
| RU2017114673A (ru) | Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение | |
| Ruf et al. | Role of the protein C receptor in cancer progression | |
| Jankun | COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential drugs. | |
| Ranasinghe et al. | A novel coagulation inhibitor from Schistosoma japonicum | |
| JP2018537089A5 (enExample) | ||
| Cherifi et al. | Bioactive molecules derived from snake venoms with therapeutic potential for the treatment of thrombo-cardiovascular disorders associated with COVID-19 | |
| Pike et al. | Serpins: finely balanced conformational traps | |
| JP2017508806A5 (enExample) | ||
| Li et al. | Intrahepatic metastases may be specific to hepatocellular carcinoma due to the coagulation and fibrinolytic systems |